| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/26/2009 | US20090082317 Low-calcemic 16,23-diene 25-oxime analogs of 1alpha,25-dihydroxy vitamin d3 |
| 03/26/2009 | US20090082314 Targeting Prodrugs for the Treatment of Gastrointestinal Diseases |
| 03/26/2009 | US20090082313 Multikinase Inhibitors for Use in the Treatment of Cancer |
| 03/26/2009 | US20090082312 Deuterium-enriched zoledronic acid |
| 03/26/2009 | US20090082308 histone deacetylase inhibitors; antiproliferative; antineoplastic; thioredoxin (TRX)-mediated diseases such as autoimmune, allergy, inflammatory diseases; and neurodegenerative diseases; hydroxamic acid moiety; 6-Carbamoylmethyl-benzo[b]thiophene-2-carboxylic acid (4-amino-1-phenyl-1H-pyrazol-3-yl)amide |
| 03/26/2009 | US20090082307 Culturing Lac Z-Y+ E. coli cell on glycerol and glucose in presence of lactose as exogenous precursor and isopropyl beta -D-thiogalactoside as inducer under conditions inducing the internalization according to a mechanism of active transport of exogenous precursor by cell and production of lactose |
| 03/26/2009 | US20090082304 Methods of Treating Hematological Malignancies with Nucleoside Analog Drugs |
| 03/26/2009 | US20090082295 Combinations and methods of using an immunomodulatory oligodeoxynucleotide |
| 03/26/2009 | US20090082294 Diagnosis, prevention and treatment of cancer |
| 03/26/2009 | US20090082292 inhibiting angiogenesis; corneal graft rejection; age related macular degeneration; diabetic retinopathy; dermatological disease |
| 03/26/2009 | US20090082289 Adenoviral vectors having a protein IX deletion |
| 03/26/2009 | US20090082279 Treating a condition associated with breakdown of the blood brain barrier by administering a peptide antagonist of zonulin that binds to the zonula occludens receptor, especially in the brain, yet does not physiologically modulate the opening of mammalian tight junctions |
| 03/26/2009 | US20090082277 Potentiation of anticancer agents |
| 03/26/2009 | US20090082265 Compositions and methods for treating diseases |
| 03/26/2009 | US20090082258 Means and Methods for Treating Advanced Stage Neuroblastoma |
| 03/26/2009 | US20090081792 Immune potentiating compositions of cancer cells |
| 03/26/2009 | US20090081729 Compositions and Methods Comprising a Ligand of ChemerinR |
| 03/26/2009 | US20090081660 Compositions and methods for the diagnosis and treatment of tumor |
| 03/26/2009 | US20090081635 Modified heparinase iii and methods of sequencing therewith |
| 03/26/2009 | US20090081283 Tumor therapy with non-viral-based high affinitiy laminin receptor-targeted vectors |
| 03/26/2009 | US20090081282 Pharmaceutical composition for treating cancer |
| 03/26/2009 | US20090081250 Compositions and methods for treatment of cervical cancer |
| 03/26/2009 | US20090081242 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 03/26/2009 | US20090081241 comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein |
| 03/26/2009 | US20090081240 Human Anti-Kir Antibodies |
| 03/26/2009 | US20090081237 Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents |
| 03/26/2009 | US20090081233 Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| 03/26/2009 | US20090081232 Methods of treating diseases with anti-vegf antibodies |
| 03/26/2009 | US20090081228 Cyr61 compositions and methods |
| 03/26/2009 | US20090081227 Promotong differentiation of neural stem cells to nerve cells for use in treating injury to central nerve system caused by brain infarction, hemorrhage and/or spinal cord injury |
| 03/26/2009 | US20090081223 Fixed dosing of her antibodies |
| 03/26/2009 | US20090081216 Treatment of pathologies which escape the immune response, using optimized antibodies |
| 03/26/2009 | US20090081215 Genetic products differentially expressed in tumors and use thereof |
| 03/26/2009 | US20090081214 Genetic products differentially expressed in tumors and use thereof |
| 03/26/2009 | US20090081209 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins |
| 03/26/2009 | US20090081208 Optimized Fc variants and methods for their generation |
| 03/26/2009 | US20090081200 Tissue Factor Antibodies and Uses Thereof |
| 03/26/2009 | US20090081195 Inhibitors of Ste20-like Kinase (SLK) and Methods of Modulating Cell Cycle Progression and Cell Motility |
| 03/26/2009 | US20090081175 Method for Treating Disseminated Cancer |
| 03/26/2009 | US20090081161 Treatment of neoplasms with viruses |
| 03/26/2009 | US20090081155 Use of Inhibitors of Indoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities |
| 03/26/2009 | US20090081131 Tumor therapy with high affinity laminin receptor-targeted vectors and compounds |
| 03/26/2009 | US20090081122 Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant |
| 03/26/2009 | CA2711818A1 Method of reducing the effects of cytostatic drugs on bone marrow derived cells, and methods of screening |
| 03/26/2009 | CA2700443A1 Certain substituted amides, method of making, and method of use thereof |
| 03/26/2009 | CA2700338A1 Anti-aids, anti-tumor, immune system stimulating herbal composition and production method |
| 03/26/2009 | CA2700327A1 Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof |
| 03/26/2009 | CA2700276A1 Inhibition of angiogenesis |
| 03/26/2009 | CA2700058A1 Novel tetrahydrofusedpyridines |
| 03/26/2009 | CA2699998A1 Compositions comprising stat5 sirna and methods of use thereof |
| 03/26/2009 | CA2699995A1 Compositions comprising stat3 sirna and methods of use thereof |
| 03/26/2009 | CA2699944A1 Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| 03/26/2009 | CA2699936A1 Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| 03/26/2009 | CA2699888A1 Combretum laurifolium mart. extract and methods of extracting and using such extract |
| 03/26/2009 | CA2699849A1 Inhibitors of the interaction between mdm2 and p53 |
| 03/26/2009 | CA2699817A1 Benzimidazole nf- kappab inhibitors |
| 03/26/2009 | CA2699761A1 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
| 03/26/2009 | CA2699707A1 Inhibitors of the interaction between mdm2 and p53 |
| 03/26/2009 | CA2699417A1 S1p receptor modulating compounds and use thereof |
| 03/26/2009 | CA2699394A1 Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| 03/26/2009 | CA2699292A1 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 03/26/2009 | CA2698814A1 Treatment of oestrogen dependant conditions in pre-menopausal women |
| 03/26/2009 | CA2697896A1 Ctl inducer composition |
| 03/26/2009 | CA2696776A1 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
| 03/26/2009 | CA2696634A1 Monoclonal antibodies against human acidic and basic ferritins and nucleotide and amino acid sequences thereof |
| 03/26/2009 | CA2693116A1 6-cycloamino-s-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof |
| 03/25/2009 | EP2039766A1 Immunocompetent cell having anti-cd38 antibody on its cell surface |
| 03/25/2009 | EP2039704A1 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| 03/25/2009 | EP2039683A2 Vasculostatic agents and methods of use thereof |
| 03/25/2009 | EP2039358A1 Pharmaceutical compositions comprising a macrolide and an acid |
| 03/25/2009 | EP2039355A2 Topical use of valproic acid for the prevention or treatment of skin disorders |
| 03/25/2009 | EP2039350A1 Method of separating vesicle, process for producing medicinal preparation, and method of evaluation |
| 03/25/2009 | EP2038414A2 Cancer therapy using bcl-xl-specific sina |
| 03/25/2009 | EP2038306A1 Anti-nkg2a antibodies and uses thereof |
| 03/25/2009 | EP2038288A1 Novel 4-amino-3-(-azolyl-phenoxymethyl)-thienoý3,2¨pyridine-7-carboxylic acid derivatives |
| 03/25/2009 | EP2038265A2 Human protein tyrosine phosphatase inhibitors and methods of use |
| 03/25/2009 | EP2038259A1 Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same |
| 03/25/2009 | EP2038258A1 5-urea substituted naphthalimide derivatives, methods of production and pharmaceutical compositions for treating cancer |
| 03/25/2009 | EP2038257A1 N-oxides of diarylurea derivatives and their use as chk1 inhibitors for the treatment of cancer |
| 03/25/2009 | EP2038041A2 Therapeutic compounds and their use in cancer |
| 03/25/2009 | EP2037966A2 Sialoadhesin-related compositions and methods |
| 03/25/2009 | EP2037950A2 Further medical uses of antisecretory protein |
| 03/25/2009 | EP2037941A1 Cobalamin compositions and methods for treating or preventing mucositis |
| 03/25/2009 | EP2037939A1 An anticancer drug comprising inhibitor of tmprss4 |
| 03/25/2009 | EP2037933A2 Combinations comprising staurosprorines |
| 03/25/2009 | EP2037931A2 Pharmaceutical combinations of pk inhibitors and other active agents |
| 03/25/2009 | EP2037919A2 Method of using substituted piperidines that increase p53 activity |
| 03/25/2009 | EP2037903A1 Combination methods of treating cancer |
| 03/25/2009 | EP2037741A1 Compositions and methods relating to novel compounds and targets thereof |
| 03/25/2009 | EP2000469A9 Acylaminopiperidine compound |
| 03/25/2009 | EP2000150A9 Titanium oxide complex particle, dispersion solution of the particle, and process for production of the particle |
| 03/25/2009 | EP1945266A4 Methods of modulating apoptosis and platelet production using variants of cytochrome c |
| 03/25/2009 | EP1824504B1 Antitumor combinations containing vegf-trap and 5fu or one of its derivatives |
| 03/25/2009 | EP1706423B1 Therapeutic and diagnostic anti-hsp 70 antibodies |
| 03/25/2009 | EP1682131B9 Cci-779 for treating mantle cell lymphoma |
| 03/25/2009 | EP1635641B1 Mitotic kinesin inhibitors |
| 03/25/2009 | EP1594885B8 Medicament for inhibiting tumour growth |
| 03/25/2009 | EP1504010B1 Vitamin-mitomycin conjugates |
| 03/25/2009 | EP1460999B1 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| 03/25/2009 | EP1380295B1 Photosensitiser and method for production thereof |